

CORPORATE RELEASE

Valby, Denmark, February 17, 2026

To the shareholders of H. Lundbeck A/S

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on:

WEDNESDAY, 18 MARCH 2026 AT 10:00 AM CET

The annual general meeting will be held at the offices of the Company at:

H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby

Agenda

In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows:

1. Report of the Board of Directors on the Company's activities during the past year.
2. Presentation and adoption of the annual report.
3. Resolution on the appropriation of profit or loss as recorded in the adopted annual report.
4. Presentation of and advisory vote on the remuneration report.
5. Election of members to the Board of Directors.
6. Approval of remuneration for the Board of Directors for the current financial year.
7. Election of one or two state-authorized public accountants.
8. Any proposals by shareholders or the Board of Directors:
 - 8.1. Proposal from the Board of Directors to authorize the Board of Directors to allow the Company to acquire treasury shares.
 - 8.2. Proposal from the Board of Directors to adopt the amended Remuneration Policy for the Board of Directors and Executive Management in its full wording. The amendment consists of an increase in maximum STI (Short term incentives) payout from 117% to 150% of the fixed annual base for Lundbeck's CEO in cases where performance exceeds the predefined targets, in order to ensure competitiveness in the talent market, drive management engagement, enhance impact of performance-based incentives and align the CEO's performance with Lundbeck's Focused Innovator Strategy.
 - 8.3. Proposal from the Board of Directors to authorize the Chair of the meeting to file the resolutions passed at the annual general meeting for registration with the Danish Business Authority.
9. Any other business.

Complete proposals

Re agenda item 1:

The Board of Directors recommends that the report be adopted.

Re agenda item 2:

The Board of Directors proposes that the annual report be approved.

Re agenda item 3:

The Board of Directors proposes to distribute a dividend of DKK 1.15 per share or a total dividend of DKK 1,145 million. The proposed dividends correspond to approximately 36% of the net profit and 30% of net profit adjusted for the impairment loss of the planned divestment of a non-core production site in Italy.

Re agenda item 4:

The Board of Directors recommends that the report be approved.

Re agenda item 5:

The Board of Directors of H. Lundbeck A/S should consist of persons who together possess the financial, pharmaceutical, and international qualifications required for safeguarding the Company's and, thus, the shareholders' interests in the best manner possible having regard to the Company's other stakeholders. The Board of Directors' most important duties are to formulate H. Lundbeck A/S' overall strategy, set specific objectives for the Company's Executive Management and ensure that the members of the Executive Management have the right qualifications.

For a more detailed description of the qualifications required for members of the Board of Directors, please see the Company's website: <https://www.lundbeck.com/global/about-us/corporate-governance/board-tasks>.

Members of the Board of Directors elected by the annual general meeting are elected or re-elected every year, and therefore the term of office of the current members expires in connection with this annual general meeting. The Board of Directors proposes that the following members elected by the annual general meeting should be re-elected: Dorothea Wenzel, Lene Skole-Sørensen, Lars Erik Holmqvist, Jeffrey Berkowitz, Santiago Arroyo, Jakob Riis, and Lars Green. In addition, the Board of Directors proposes to elect Rita Balice-Gordon as a new member of the Board of Directors. The Board of Directors expects to elect Dorothea Wenzel as Chair and to elect Lene Skole-Sørensen as Deputy Chair.

The Board of Directors assesses that together, the candidates possess the professional and international experience required for maintaining the Company's position as a leading global pharmaceutical company focusing on research and development in the field of brain disorders. The Board of Directors also considers the size of the Board appropriate considering the Company's needs and the aim of ensuring constructive debate and effective decision-making. Regard has been given to diversity in the selection of board candidates.

The Recommendations on Corporate Governance recommend that at least half of a company's board members elected by the annual general meeting should be independent of the Company. Dorothea Wenzel, Jeffrey Berkowitz, Santiago Arroyo, Lars Green and Rita Balice-Gordon meet the criteria for independence. Lene Skole-Sørensen and Lars Erik Holmqvist are considered to be non-independent board members due to their responsibilities in the Lundbeck Foundation. Jakob Riis is considered to be a non-independent board member due to his position as CEO in Falck A/S, where the Lundbeck Foundation is a significant shareholder. If the proposed candidates are elected to the Board of Directors, the Board

will meet the recommendation for independence as defined by the Recommendations on Corporate Governance.

The following persons were elected to the Board of Directors in 2022 for a four-year period as employee representatives in accordance with the Danish Companies Act (Selskabsloven): Hossein Armandi, Lasse Skibsbye, Dorte Clausen and Camilla Gram Andersson. Their election term will end after the annual general meeting. New employee representatives will prior to the annual general meeting be elected for a three-year period and the results of the election will be presented at the annual general meeting.

The proposed board candidates to be elected by the annual general meeting have the following backgrounds:

Dorothea Wenzel

Dorothea Wenzel holds a PhD in Health Economics & Macroeconomics and a M.Sc. in Business & Computer Sciences from the University of Darmstadt in Germany. She has also held fellowships at Harvard and was a visiting student at the University of California at Berkley. Dorothea Wenzel was born in 1969 and is a German citizen. She was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2021 Annual General Meeting. She is the Chair of the Board of Directors of H. Lundbeck A/S and chairs the Remuneration & Nomination Committee and is a member of the Scientific Committee.

Dorothea Wenzel is an independent Board member. She had a long career at Merck KGaA, headquartered in Darmstadt, Germany, where she most recently until August 2021 served as Executive Vice President and Head of the Global Business Unit Surface Solutions. In 2018 she was the CFO & Head of Strategy of the Performance Materials Division, from 2014 to 2018 she headed Merck's Global Fertility Business Franchise, and from 2005 to 2013 she was the CFO of Merck's Healthcare division. Prior to Merck she worked at McKinsey & Comp., with an e-commerce startup and for a German governmental commission.

Dorothea Wenzel's special qualifications for serving on H. Lundbeck A/S' Board of Directors include an impressive track record in Finance and Strategy leadership across multiple industries. She further strengthens the Board's competencies in finance and business transformation to ensure the company remains best set for the future.

Dorothea Wenzel is a member of the Supervisory Board (Chair of Audit Committee) of Servier Group and a member of the Board of Directors of WS Audiology A/S (Chair of Audit Committee).

Lene Skole-Sørensen

Lene Skole-Sørensen, BCom Finance, was born in 1959 and is a Danish citizen. She was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2015 Annual General Meeting. She is the Deputy Chair of the Board of Directors of H. Lundbeck A/S and a member of the Remuneration & Nomination Committee and Scientific Committee.

Lene Skole-Sørensen is the CEO at the Lundbeck Foundation CEO at Lundbeckfond Invest A/S and Chair of the Board of Directors at LFI Equity A/S. Prior to joining the Lundbeck Foundation in 2014, Lene Skole-Sørensen was CFO at Coloplast A/S, where she was a member of the company's executive management since joining in 2005. Lene Skole-Sørensen's responsibilities included finance, IT, HR, communication,

strategy and M&A. Before 2005, Lene Skole-Sørensen held various positions in the AP Moller-Maersk group, most recently as CFO of Maersk Company Ltd., London from 2000-2005.

Lene Skole-Sørensen's special qualifications for serving on H. Lundbeck A/S' Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech.

Lene Skole-Sørensen is Chair of the Board of Directors of Ørsted A/S, Chair of the Board of LFI Equity A/S, Deputy Chair of the Board of Directors of Falck A/S, Nordea Bank Abp, and ALK-Abelló A/S and executive manager of Skole Invest ApS.

Lars Erik Holmqvist

Lars Erik Holmqvist, MSc in business administration, was born in 1959 and is a Swedish citizen. He was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2015 Annual General Meeting. He is member of H. Lundbeck A/S' Audit Committee.

Lars Erik Holmqvist was Senior Advisor within healthcare at Bain Capital Private Equity. He previously served as Vice President responsible for sales and marketing at Pharmacia. In addition, he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO A/S and Agilent Technologies.

Lars Erik Holmqvist's special qualifications for serving on H. Lundbeck A/S' Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.

Lars Erik Holmqvist is member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S and Vitrolife AB.

Jeffrey Berkowitz

Jeffrey Berkowitz, Juris Doctor and BA in Political Science, was born in 1966 and is a US citizen. He was first nominated for election to the H. Lundbeck A/S' Board of Directors at the 2018 Annual General Meeting and is a member of H. Lundbeck A/S' Audit Committee and Remuneration & Nomination Committee.

Jeffrey Berkowitz is currently CEO of Real Endpoints, a leader in the development and implementation of proprietary tools to strengthen market access for biopharmaceutical companies. Prior to this, Jeffrey Berkowitz recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as an Executive Committee member and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2014 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co, then as President of Walgreens Boots Alliance Development in the period 2010 to 2015. From 1998 to 2010, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.

Jeffrey Berkowitz's special qualifications for serving on H. Lundbeck A/S' Board of Directors include proven results and global experience with payers, pharmaceutical companies, specialty and retail pharmacies and drug distributors with deep experience in generic and branded procurement and inventory

management, as well as pricing, reimbursement, specialty pharmacy distribution and health care strategies. He is a sought after thought leader and speaker in the area of pharmaceutical market access and reimbursement and has extensive public board and committee experience.

Jeffrey Berkowitz is a member of the Board of Directors of Zealand Pharma A/S and Click Therapeutics.

Santiago Arroyo

Dr. Santiago Arroyo, MD and PhD, was born in 1960 and is a US citizen.

He was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2021 Annual General Meeting and he chairs H. Lundbeck's A/S' Scientific Committee.

Dr. Arroyo has more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology.

In 2003, Dr. Arroyo joined the pharmaceutical industry and has held a variety of positions in clinical research and development - most recently as Chief Development Officer at Bicycle Therapeutics. Prior to this, Dr. Arroyo served as Chief Medical Officer at Fulcrum Therapeutics and Momenta Pharmaceuticals. Before that, he held roles of Senior Vice President, Head of Clinical Research, and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., Therapeutic Area Head for Neurosciences, Discovery Medicine, and Clinical Pharmacology at Bristol-Myers Squibb, and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development.

Dr. Arroyo's special qualifications for serving on H. Lundbeck A/S' Board of Directors include his therapeutic and deep scientific expertise in neuroscience and beyond as well as strategic and business vision.

Santiago Arroyo serves as a member of the Board of Directors at GlycoEra AG and Maxion Therapeutics.

Jakob Riis

Jakob Riis earned his master's degree in Forestry in 1992 and a PhD in Econometrics in 1996 from The Royal Veterinary and Agricultural University. He was born in 1966 and is a Danish citizen. He was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2023 Annual General Meeting and is a member of H. Lundbeck A/S' Scientific Committee.

Jakob Riis is currently the CEO at Falck A/S. Jakob Riis has more than 25 years of experience in management and sales & marketing in the international healthcare industry. He previously worked at Novo Nordisk for 20 years in various positions in the commercial area (U.S. sales organization, Japan, Head of Marketing for more than a decade, and most recent as President of the North American business, member of the Executive Management).

Jakob Riis' special qualifications for serving on H. Lundbeck A/S' Board of Directors include his proven track record in pharmaceutical value chain management from early-stage assets, production planning, registration trials, label negotiations, market access and global commercialization. In addition, he has extensive experience in operating in a listed company and with market communication.

As mentioned above, Jakob Riis is currently CEO of Falck A/S and holds 3 directorships in Falck A/S subsidiaries. He is deputy chair of the Board of Directors of the Danish Chamber of Commerce and Nordhavn Training Club ApS, and executive manager of Adelca ApS.

Lars Green

Lars Green, MSc in business administration, was born in 1967 and is a Danish citizen. He was first nominated for election to H. Lundbeck A/S' Board of Directors at the 2025 Annual General Meeting and he chairs H. Lundbeck's A/S' Audit Committee.

He is a professional board member with more than 30 years of experience from global pharmaceutical and life science industries, most recently as CFO of Novozymes from 2019 to 2023, where he stepped down following the successful formation of Novonosis through the merger with Chr. Hansen. Prior hereto, Lars spent more than 25 years with Novo Nordisk in various leadership roles, including regional CFO roles in both Japan and North America, and as head of Group Finance. The last two years he served on the Executive Management team with global responsibility for P&O, IT, Quality, Compliance and shared service functions.

Lars Green's special qualifications for serving on H. Lundbeck A/S' Board of Directors include his international management experience in global pharmaceutical and life science companies. In addition, he has extensive experience in financial management, corporate governance and interaction with investors and the financial markets.

Lars Green currently serves on the Board of Trustees of LEO Foundation and the Board of Directors of LEO Holding A/S, LEO Pharma A/S where he is also chairing the Audit Committee. He is on the Board of Trustees in Novo Nordisk Foundation and chair of the Board of Directors in Novo Holdings A/S. In addition, he is member of the board of Pharmacosmos A/S, Green Housing ApS, Nordic Storm Holding A/S and the Committee on Corporate Governance, and is executive manager of Green & Niemann Invest ApS and LG Invest 2024 ApS.

Rita Balice-Gordon

Rita Balice-Gordon, PhD in Neurobiology, was born in 1960 and is a US citizen. She meets the criteria for being considered an independent Board member.

Rita Balice-Gordon is currently the Chief Executive Officer of Muna Therapeutics, a biotechnology company focused on discovering and developing disease-modifying therapies for neurodegenerative diseases. In parallel, she serves as Adjunct Professor of Neuroscience at the University of Pennsylvania, where she was a tenured professor from 1994 to 2015 before continuing her academic engagement as an adjunct professor.

Prior to joining Muna Therapeutics, Rita Balice-Gordon served as Entrepreneur in Residence at Novo Seeds / Novo Ventures from 2020 to 2021. From 2016 to 2020, she held the position as Global Head of the Rare and Neurologic Diseases Therapeutic Area at Sanofi. Earlier, from 2012 to 2016, she was Vice President and Head of Circuits, Neurotransmitters and Signaling at Pfizer. Through these roles, she has gained extensive experience spanning translational research, portfolio strategy, and leadership of complex R&D organizations.

Rita Balice-Gordon's special qualifications for serving on the Board of Directors of H. Lundbeck A/S include her deep scientific and R&D expertise within neuroscience and neurodegenerative diseases, her proven ability to develop and execute strategy in complex and innovation-driven organizations, and her experience operating across academic, biotechnology, and global pharmaceutical environments. She further strengthens the Board's competencies by contributing a strong U.S. perspective and by supporting Lundbeck's continued focus on innovation and disease-modifying treatments within brain health.

Rita Balice-Gordon currently serves on the Board of Directors of Collegium Pharmaceuticals and Capsida Biotherapeutics.

Re agenda item 6:

It is proposed that the Board of Directors should receive the following remuneration for 2026:

- Ordinary members will receive a base fee of DKK 450,000.
- The Chair will receive three times the base fee.
- The Deputy Chair will receive two times the base fee.
- Ordinary members of the board committees will receive DKK 200,000 in addition to the base fee.
- The committee chairs will receive DKK 300,000 in addition to the base fee.
- Board members with permanent residence outside of Europe will as compensation for time and travel receive DKK 400,000 in addition to the base fee.

Re agenda item 7:

In accordance with the recommendation submitted to the Board of Directors by the Audit Committee, the Board of Directors proposes that PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no.: 33 77 12 31 should be re-elected as auditor for the Company, which will include the task of auditing the Company's sustainability reporting. The Audit Committee is free from influence by a third party and is not subject to a contract with a third party restricting the choice of the annual general meeting to certain categories or lists of statutory auditors or audit firms, as regards the appointment of a particular statutory auditor or audit firm to carry out the statutory audit of the Company.

Re agenda item 8:

- 8.1 It is proposed to authorize the Board of Directors until the next annual general meeting to allow the Company to acquire treasury shares of a total nominal value of up to 10% of the share capital. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A/S at the time of the acquisition.
- 8.2 The Board of Directors proposes to adopt the amended Remuneration Policy for the Board of Directors and the Executive Management of H. Lundbeck A/S in its full wording.

The amendment consists of an increase in maximum STI (short term incentives) payout for Lundbeck's CEO from 117 % to 150% of the fixed annual base salary in cases where performance exceeds the predefined targets in order to ensure competitiveness in the talent market, drive

management engagement, enhance impact of performance based incentives and align the CEO's performance with Lundbeck's Focused Innovator Strategy.

The proposed amended Remuneration Policy for the Board of Directors and the Executive Management of H. Lundbeck A/S with amendments in mark-up is enclosed as appendix 1.

- 8.3 The Board of Directors proposes to authorize the Chair of the annual general meeting to make such amendments and additions to the resolutions passed by the annual general meeting and the application for registration with the Danish Business Authority that may be required by the Danish Business Authority in connection with the registration of the adopted amendments.

All proposals on the agenda may be adopted by a simple majority of votes.

PRACTICAL INFORMATION

H. Lundbeck A/S welcomes all shareholders who have obtained an admission card for themselves and for any adviser accompanying them at the annual general meeting. Please note that admission cards must be obtained prior to the annual general meeting in order to attend. Due to construction work in our usual reception area, access to the annual general meeting is via the temporary reception on Ottillievej 9, DK-2500 Valby on the opposite side of Ottillievej from our usual reception. There is limited parking space available on Ottillievej and Krumtappen, where parking is allowed for up to three hours (remember to set the parking disc). Due to the parking rules in the area, it is not possible to purchase extra parking time, and no guest tickets or guest licenses are issued.

If you have functional impairments which make passage from the entrance to the auditorium difficult, you may request assistance from the staff upon arrival at the reception.

Registration, admission cards and notice of attendance (requirement for attending the annual general meeting)

In accordance with Article 10.1 of the Articles of Association, admission cards will be provided to shareholders entitled to vote at the annual general meeting. **Anyone who is registered as a shareholder in the register of shareholders on the date of registration, 11 March 2026, or who has made a request to such effect, including evidence of title to shares, that has reached the Company on that date, is entitled to vote at the annual general meeting** (see Article 10.4 of the Articles of Association).

Admission cards for the annual general meeting can be obtained up to and including 13 March 2026 online through the investor portal, [Investor Portal](#), or by returning the admission card request form to Computershare A/S, Lottenborgvej 26 D, 1. sal, DK-2800 Kgs. Lyngby, tel. +45 4546 0997.

Admission cards will be sent out electronically via email to the email address specified in the investor portal upon registration. The admission card must be presented at the annual general meeting either electronically on a smartphone/tablet or in print.

Shareholders who have ordered admission cards without specifying their email address can pick up the admission card at the entrance of the annual general meeting upon presentation of valid ID.

Voting cards will be handed out at the entrance of the annual general meeting.

Questions

All shareholders may ask written questions about the agenda and the documents to be used for the annual general meeting. Questions may be sent by e-mail to info@lundbeck.com and will be answered prior to or at the annual general meeting.

Voting by proxy or by postal votes

If you wish to submit your votes ahead of the annual general meeting or you are not attending the annual general meeting, the Board of Directors would be pleased to act as proxy to cast the votes attached to your shares, in which case the proxy form, duly completed, dated and signed, must reach Computershare A/S, Lottenborgvej 26 D, 1. sal, DK-2800 Kgs. Lyngby, by 13 March 2026. If you wish to appoint someone other than the Board of Directors as proxy, the form for appointing a third party as proxy can be used. The proxy forms are available on the Company's website, [General meeting \(lundbeck.com\)](https://www.lundbeck.com). Proxies may also be appointed electronically via the investor portal, [Invester Portal](https://www.lundbeck.com/global/investors), on or before 13 March 2026 (please use custody account number and access code or the Danish MitID).

You may also vote by post by completing and signing the postal voting form and returning it to Computershare A/S, Lottenborgvej 26 D, 1. sal, DK-2800 Kgs. Lyngby, so that it is received by 17 March 2026 at 12 noon CET. A postal voting form is available on the Company's website, [General meeting \(lundbeck.com\)](https://www.lundbeck.com), where votes may also be cast electronically via the investor portal, <https://www.lundbeck.com/global/investors>.

Documents available on Lundbeck.com

The following information and documents will be made available on the Company's website, [General meeting \(lundbeck.com\)](https://www.lundbeck.com) no later than 17 February 2026: 1) The notice convening the annual general meeting; 2) the total number of shares and voting rights at the date of the notice; 3) all documents to be submitted to the annual general meeting, including the audited annual report, the remuneration report, and the proposed amended Remuneration Policy; 4) the agenda and the full text of all proposals to be submitted to the annual general meeting; and 5) postal and proxy voting forms.

The size of the share capital and voting right

The Company's nominal share capital is DKK 995,741,110 divided into A-share capital of DKK 199,148,222 and B-share capital of DKK 796,592,888. Each A-share of a nominal value of DKK 1 carries ten votes and each B-share of a nominal value of DKK 1 carries one vote as provided by Article 10.6 of the Articles of Association.

Language

H. Lundbeck A/S offers simultaneous interpretation from Danish into English in the Auditorium. Presentation and answers provided by our Chair of the Board of Directors and CEO in English will be simultaneously interpreted from English to Danish.

Webcast

It will also be possible to follow the annual general meeting via live webcast in Danish and English, which can be watched live or replayed after the meeting, see the Company's website www.lundbeck.com.

Personal data

As a shareholder in H. Lundbeck A/S, we will process your ordinary personal data for the purpose of keeping a register of H. Lundbeck A/S' investors, for analyzing the composition of investors and for being able to communicate effectively with investors, including when sending this invitation to the annual general meeting. Further, H. Lundbeck A/S will process your personal data in connection with your participation at the annual general meeting, including in connection with issuing and use of proxies, if you put forward proposals to be handled at the annual general meeting, if you raise questions to H. Lundbeck A/S prior to or at the annual general meeting, or if you have a commentary to be read out at the annual general meeting. You can read more about H. Lundbeck A/S' handling and processing of your personal data in connection with the annual general meeting on the Company's website www.lundbeck.com.

Valby, 17 February 2026

The Board of Directors H. Lundbeck A/S

Contacts

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com
+45 30 83 45 01

Anders Crillesen
Head of Media Relations, Corp. Communication
AECE@lundbeck.com
+45 29 79 12 86

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

Safe Harbor/Forward-Looking Statements

This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this corporate release, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and in oral presentations made on behalf of Lundbeck speak only as at the date of this document. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this corporate release or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the release, presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.